Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Single-arm, Open-label Extension Study to Evaluate the Safety of Finerenone in Addition to Standard of Care, in Pediatric Heart Failure Patients, From Birth to 18 Years of Age, With Left Ventricular Systolic Dysfunction (LVSD)

NCT07192952 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT07192952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07192952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Single-arm, Open-label Extension Study to Evaluate the Safety of Finerenone in Addition to Standard of Care, in Pediatric Heart Failure Patients, From Birth to 18 Years of Age, With Left Ventricular Systolic Dysfunction (LVSD)
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Recruiting
Start date
June 1, 2026
Completion date
December 30, 2030
Enrollment
117 (estimated)
Sites
132

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure (pediatric), left ventricular systolic dysfunction